Fujifilm Holdings Corp.'s new president, Kenji Sukeno, aims to make its pharmaceutical operations profitable and said the company will consider acquisitions to bolster growth in sectors where it has an existing presence.

The company is targeting 20 percent operating margins in its drug operations and aims to make the business profitable in the fiscal year starting April 2018, Sukeno said in an interview in Tokyo.

Last March, Fujifilm agreed to pay $307 million for U.S.-based Cellular Dynamics International Inc., a producer of iPS cells, a type of stem cell capable of morphing into any body part. The hope is that its regenerative medicine units could someday create cells to help damaged organs like the liver or pancreas grow again.